secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acrivon Therapeutics, Inc. (ACRV)
CIK:        0001781174
Form:       8-K
Filed at:   2026-05-13T20:10:18+00:00
Accession:  0001193125-26-221626
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acrivon Q1 net loss $19.0M; cash $97.7M; key ACR-368 interim readout in H2 2026
-------------------------------------------------------------------------------

- Net loss $19.0M vs $19.7M YoY; R&D $15.2M, G&A $4.7M.
- Cash & equivalents $97.7M at March 31, 2026; plus $7.3M from equity financing, runway into Q3 2027.
- ACR-368 Phase 2b registrational study: prespecified interim analysis of serous EC arms planned in H2 2026.
- ACR-2316 Phase 1/2 shows tolerability and durable activity in AP3-prioritized lung cancers; expansion phase ongoing.
- CDK11 inhibitor program (ACR-6840) IND submission targeted for H1 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781174/000119312526221626/0001193125-26-221626-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781174/000119312526221626/acrv-20260513.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-221626

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer